|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.11.25 - 22:06
|
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire)
|
|
|
Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026
KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date
Leadership updates with the appointments of Dr. Syed Rizvi, Chief Medical Officer, Christopher Stevens, Chief Operating Officer, and Sarbani Chaudhuri, Chief Commercial & Medical Affairs Officer
Cash, cash equivalents and investments of approximately $222.8M; expected operational runway into the second quarter of 2027
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the third quarter ending September 30, 2025.
“During the third quarter, we maintained disciplined execution and sharpened our strategic focus on Rocket's AAV cardiovascular gene therapy portfolio,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceutica...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
